var data={"title":"Methylprednisolone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methylprednisolone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6567?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">see &quot;Methylprednisolone: Drug information&quot;</a> and <a href=\"topic.htm?path=methylprednisolone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methylprednisolone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50579346\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">SOLU-MEDROL ACT-O-VIAL 40 mg Safety Information</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada is alerting that severe hypersensitivity reactions in patients hypersensitive to milk following the use of Pfizer Canada's SOLU-MEDROL ACT-O-VIAL (methylprednisolone sodium succinate for injection) 40 mg have been internationally reported in the postmarketing setting. SOLU-MEDROL ACT-O-VIAL 40 mg, the only SOLU-MEDROL formulation available in Canada containing bovine-sourced lactose as an excipient, is contraindicated in patients with a known or suspected hypersensitivity to cow's milk. Alternative treatments, including corticosteroid formulations that do not contain bovine-sourced ingredients, should be considered for acute allergy management in patients allergic to cow's milk proteins due to the potential for SOLU-MEDROL ACT-O-VIAL 40 mg to exacerbate the condition.</p>\n        <p style=\"text-indent:0em;\">The Canadian Product Monograph has been updated to reflect this new safety information. Further information may be found at http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/64350a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195382\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>DEPO-Medrol;</li>\n      <li>Medrol;</li>\n      <li>P-Care D40;</li>\n      <li>P-Care D80;</li>\n      <li>ReadySharp Methylprednisolone;</li>\n      <li>SOLU-medrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195383\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Depo-Medrol;</li>\n      <li>Medrol;</li>\n      <li>Methylprednisolone Acetate;</li>\n      <li>Methylprednisolone Sodium Succinate For Injection;</li>\n      <li>Methylprednisolone Sodium Succinate For Injection USP;</li>\n      <li>Solu-Medrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053999\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Systemic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053992\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">see &quot;Methylprednisolone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed. <b>Only sodium succinate salt may be given IV </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, exacerbation: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acute, short-course &ldquo;burst&rdquo;</i> (NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 1 to 2 mg/kg/day in divided doses once or twice daily for 3 to 10 days; maximum daily dose: 60 mg/<b>day</b>; <b>Note:</b> Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IM <b>(acetate)</b>: <b>Note:</b> This may be given in place of short-course &ldquo;burst&rdquo; of oral steroids in patients who are vomiting or if compliance is a problem.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children &le;4 years: 7.5 mg/kg as a one-time dose; maximum dose: 240 mg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children 5 to 11 years: 240 mg as a one-time dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 40 to 60 mg/day in divided doses once or twice daily for 3 to 10 days; <b>Note:</b> Burst should be continued until symptoms resolve and peak expiratory flow is at least 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IM <b>(acetate)</b>: 240 mg as a one-time dose; <b>Note:</b> This may be given in place of short-course &ldquo;burst&rdquo; of oral steroids in patients who are vomiting or if compliance is a problem</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hospital/emergency medical care doses: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: Oral, IV: 1 to 2 mg/kg/day in 2 divided doses; maximum daily dose: 60 mg/<b>day</b>; continue until peak expiratory flow is 70% of predicted or personal best</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Oral, IV: 40 to 80 mg/day in divided doses once or twice daily until peak expiratory flow is 70% of predicted or personal best</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Status asthmaticus</i> (previous NAEPP guidelines; still used by some clinicians): Children: IV: Loading dose: 2 mg/kg/dose, then 0.5 to 1 mg/kg/dose every 6 hours; <b>Note:</b> See NAEPP 2007 guidelines for asthma exacerbations (emergency medical care or hospital doses) listed above</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, long-term treatment (maintenance)</b> (NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: Oral: 0.25 to 2 mg/kg/day once daily in the morning or every other day as needed for asthma control; maximum daily dose: 60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 7.5 to 60 mg daily once daily in the morning or every other day as needed for asthma control</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing; anti-inflammatory or immunosuppressive:</b> Infants, Children, and Adolescents: <b>Note:</b> Dosing range variable; individualize dose for disease state and patient response; Oral, IM (acetate or succinate), IV (succinate): Initial: 0.11 to 1.6 mg/kg/day or 3.2 to 48 mg/m<sup>2</sup>/day; usual range: 0.5 to 1.7 mg/kg/day (Kliegman 2015); for oral, IM (succinate) and IV (succinate) administer in divided doses every 6 to 12 hours; for IM (acetate) administer as a single daily dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ldquo;Pulse&rdquo; therapy: IV (succinate): 15 to 30 mg/kg/dose once daily for 3 days; maximum dose: 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Long-acting: IM (acetate): 4 to 80 mg every 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease:</b> Limited data available; optimal regimen not established; efficacy variable.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary treatment, patients at high risk for coronary artery aneurysms:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pulse dosing: Infants and Children: IV: 30 mg/kg/dose as a single dose in combination with IVIG and aspirin (AHA [McCrindle 2017]; Ogata 2012; Okada 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Taper dosing: Infants and Children: IV: 1.6 mg/kg/day in divided doses every 8 hours for 5 days or until afebrile, then transition to oral prednisolone; maximum daily dose: 48 mg/<b>day</b>; give in combination with aspirin and an additional dose of IVIG (AHA [McCrindle 2017]; Kobayashi 2012). <b>Note:</b> Dosing based on use of IV prednisolone product (2 mg/kg/day) which is not available in US; dosing converted to equivalent methylprednisolone dosing; however, clinical necessity of conversion is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment, refractory/resistant disease: </i>\n      <b>Note:</b> Reserve use for patients who remain febrile after initial IVIG dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pulse dosing: Infants and Children: IV: 30 mg/kg/dose once daily for 1 or 3 days; may be given in combination with additional IVIG dose (AHA [McCrindle 2017]; Ebato 2017; Miura 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Taper dosing: Infants and Children: IV: 1.6 mg/kg/day in divided doses every 8 hours for 5 days or until afebrile, then transition to oral prednisolone; maximum daily dose: 48 mg/<b>day</b>; give in combination with aspirin and an additional dose of IVIG (AHA [McCrindle 2017]; Kobayashi 2012; Kobayashi 2013). <b>Note:</b> Dosing based on use of IV prednisolone product (2 mg/kg/day) which is not available in US; dosing converted to equivalent methylprednisolone dosing; however, clinical necessity of conversion is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis:</b> Children and Adolescents: IV (succinate): High-dose &quot;pulse&quot; therapy: 30 mg/kg/dose or 600 to 1,000 mg/<b>m</b><sup>2</sup>/dose once daily for 3 days; maximum dose: 1,000 mg (Adams 2006; Marks 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spinal cord injury, acute:</b> Children and Adolescents: IV (succinate): 30 mg/kg over 15 minutes followed in 45 minutes by a continuous infusion of 5.4 mg/kg/hour for 23 hours; <b>Note:</b> Due to insufficient evidence of clinical efficacy (ie, preserving or improving spinal cord function), the routine use of methylprednisolone in the treatment of acute spinal cord injury is no longer recommended. If used in this setting, methylprednisolone should not be initiated &gt;8 hours after the injury; not effective in penetrating trauma (eg, gunshot) (Consortium for Spinal Cord Medicine 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis</i> pneumonia; moderate or severe infection:</b> <b>Note:</b> Initiate therapy within 72 hours of diagnosis, if possible.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: IV (succinate): 1 mg/kg/dose every 6 hours on days 1 to 7, then 1 mg/kg/dose twice daily on days 8 to 9, then 0.5 mg/kg/dose twice daily on days 10 and 11, and 1 mg/kg/dose once daily on days 12 to 16 (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV (succinate): 30 mg twice daily on days 1 to 5, then 30 mg once daily on days 6 to 10, then 15 mg once daily on days 11 to 21 (CDC 2009a)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Graft-versus-host disease, acute (GVHD):</b> Infants, Children and Adolescents: IV (succinate): 1 to 2 mg/kg/dose once daily; if using low dose (1 mg/kg) and no improvement after 3 days, increase dose to 2 mg/kg. Continue therapy for 5 to 7 days; if improvement observed, may taper by 10% of starting dose every 4 days; if no improvement, then considered steroid-refractory GVHD and additional agents should be considered (Carpenter 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic conditions:</b> Oral: Tapered-dosage schedule (eg, dose-pack containing 21 x 4 mg tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 1: 24 mg on day 1 administered as 8 mg (2 tablets) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime <b>OR</b> 24 mg (6 tablets) as a single dose or divided into 2 or 3 doses upon initiation (regardless of time of day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 2: 20 mg on day 2 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 3: 16 mg on day 3 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 4 mg (1 tablet) at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 4: 12 mg on day 4 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, and 4 mg (1 tablet) at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 5: 8 mg on day 5 administered as 4 mg (1 tablet) before breakfast and 4 mg (1 tablet) at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 6: 4 mg on day 6 administered as 4 mg (1 tablet) before breakfast</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anti-inflammatory or immunosuppressive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2 to 60 mg/day in 1 to 4 divided doses to start, followed by gradual reduction in dosage to the lowest possible level consistent with maintaining an adequate clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM (sodium succinate): 10 to 80 mg/day once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM (acetate): 10 to 80 mg every 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (sodium succinate): 10 to 40 mg over a period of several minutes and repeated IV or IM at intervals depending on clinical response; when high dosages are needed, give 30 mg/kg over a period &ge;30 minutes and may be repeated every 4 to 6 hours for 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Arthritis:</b> Intra-articular (acetate): Administer every 1 to 5 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Large joints (eg, knee, ankle): 20 to 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Medium joints (eg, elbow, wrist): 10 to 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Small joints: 4 to 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma exacerbations, including status asthmaticus (emergency medical care or hospital doses):</b> Oral, IV: 40 to 80 mg/day in 1 to 2 divided doses until peak expiratory flow is 70% of predicted or personal best (NIH Asthma Guidelines, NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, severe persistent, long-term control:</b> Oral: 7.5 to 60 mg/day (or on alternate days) (NIH Asthma Guidelines, NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatitis, acute severe:</b> IM (acetate): 80 to 120 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatitis, chronic:</b> IM (acetate): 40 to 120 mg every 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatologic conditions (eg, keloids, lichen planus):</b> Intralesional (acetate): 20 to 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomyositis/polymyositis:</b> IV (sodium succinate): 1,000 mg/day for 3 to 5 days for severe muscle weakness, followed by conversion to oral prednisone (Drake 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis:</b> High-dose &ldquo;pulse&rdquo; therapy: IV (sodium succinate): 500 to 1,000 mg/day for 3 days (Ponticelli 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis</i> pneumonia in AIDS patients:</b> IV: 30 mg twice daily for 5 days, then 30 mg once daily for 5 days, then 15 mg once daily for 11 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution; slightly dialyzable (5% to 20%); administer dose posthemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195358\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">P-Care D40: 40 mg/mL [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">P-Care D80: 40 mg/mL [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ReadySharp Methylprednisolone: 80 mg/mL [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SOLU-medrol: 500 mg (1 ea); 1000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SOLU-medrol: 2 g (1 ea) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg (1 ea); 125 mg (1 ea); 1000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SOLU-medrol: 40 mg (1 ea) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SOLU-medrol: 125 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Injection, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DEPO-Medrol: 20 mg/mL (5 mL); 40 mg/mL (5 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DEPO-Medrol: 40 mg/mL (1 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DEPO-Medrol: 80 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DEPO-Medrol: 80 mg/mL (5 mL) [contains benzyl alcohol, polyethylene glycol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DEPO-Medrol: 80 mg/mL (1 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/mL (1 mL, 5 mL, 10 mL); 80 mg/mL (1 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Injection, as acetate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 80 mg/mL (2 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medrol: 2 mg, 8 mg, 16 mg, 32 mg, 4 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8 mg, 16 mg, 32 mg, 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medrol: 4 mg (21 ea) [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg (21 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195342\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054003\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer after meals or with food or milk; do not administer with grapefruit juice; if prescribed once daily, administer dose in the early morning to mimic the normal diurnal variation of endogenous cortisol   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: <b>Acetate, Succinate:</b> Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Do not inject into areas that have evidence of acute local infection. Discard contents of single-dose vial after use. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: <b>Succinate:</b> Rate dependent upon dose; typically intermittent infusion is administered over 15-60 minutes. Do not administer moderate or high dose IV push; severe adverse effects, including hypotension, cardiac arrhythmia, and sudden death, have been reported in patients receiving high-dose methylprednisolone IV push over &lt;20 minutes (Barron 1982; Ditzian-Kadanoff 1987;  Garin 1986; Liebling 1981; Lucas 1993). <b>Do not give acetate form IV.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Low  dose (eg, &le;1.8 mg/kg or &le;125 mg/dose): IV push over 3 to 15 minutes; maximum concentration: 125 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Moderate dose (eg, &ge;2 mg/kg or 250 mg/dose): Administer over 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">High dose (eg, &ge;15 mg/kg or &ge;500 mg/dose): Administer over 30 to 60 minutes; doses &ge;1,000 mg: Administer over 60 minutes. <b>Note:</b> In some of the adult spinal cord injury trials, bolus doses (30 mg/kg) have been administered over 15 minutes.   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195375\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Methylprednisolone acetate injection and tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not autoclave vials.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Methylprednisolone sodium succinate injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Do not autoclave. Store reconstituted solutions at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) and use within 48 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054002\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Systemic: Tablets, parenteral (IV, IM): Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic, and autoimmune origin (FDA approved in ages &gt;1 month and adults); has also been used for acute spinal cord injury,  <i>Pneumocystis</i> pneumonia,  and prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Depot formulations (Depo-Medrol&reg;): [FDA approved in pediatric patients (age not specified) and adults]  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intra-articular (or soft tissue): Acute gouty arthritis, acute/subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intralesional (injectable suspension): Alopecia areata; discoid lupus erythematosus; infiltrated, inflammatory lesions associated with granuloma annulare, lichen planus, neurodermatitis, and psoriatic plaques; keloids; necrobiosis lipoidica diabeticorum; possibly helpful in cystic tumors of an aponeurosis or tendon (ganglia)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195438\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MethylPREDNISolone may be confused with medroxyPROGESTERone, methotrexate, methylTESTOSTERone, predniSONE </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DEPO-Medrol may be confused with Depo-Provera, SOLU-Medrol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medrol may be confused with Mebaral </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SOLU-Medrol may be confused with salmeterol, Solu-CORTEF</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Medrol [U.S., Canada, and multiple international markets] may be confused with Medral brand name for omeprazole [Mexico]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195434\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmia, cardiac failure, cardiomegaly, circulatory shock, edema, embolism (fat), hypertension, hypertrophic cardiomyopathy (in neonates), myocardial rupture (post MI), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Arachnoiditis, depression, emotionallability, euphoria, headache, increased intracranial pressure, insomnia, malaise, meningitis, myasthenia, neuritis, neuropathy, paraplegia, paresthesia, personality changes, psychic disorders, pseudotumor cerebri (usually following discontinuation), seizure, sensory disturbance, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, allergic dermatitis, alopecia, atrophic striae, diaphoresis, ecchymoses, epidermal thinning, erythema, exfoliation of skin, facial erythema, hyperpigmentation, hypertrichosis, hypopigmentation, skin atrophy, skin rash, suppression of skin test reaction, thinning hair, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenal suppression, calcinosis, cushingoid state, Cushing syndrome, decreased glucose tolerance, diabetes mellitus, fluid retention, glycosuria, growth suppression (children), hirsutism, HPA-axis suppression, hyperglycemia, hyperlipidemia, hypokalemia, hypokalemic alkalosis, insulin resistance (increased requirements for insulin or oral hypoglycemic agents in diabetes), menstrual disease, moon face, negative nitrogen balance, protein catabolism, sodium retention, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, bladder dysfunction (after intrathecal administration, including bowel dysfunction), carbohydrate intolerance (increased), gastrointestinal hemorrhage, gastrointestinal perforation, hiccups, increased appetite, intestinal perforation (of both of the small and large intestines; especially in patients with inflammatory bowel disease), nausea, pancreatitis, peptic ulcer, spermatozoa disorder (decreased motility and number of spermatozoa), ulcerative esophagitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic: Leukocytosis (transient), malignant neoplasm (secondary), petechia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly, increased liver enzymes, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Increased susceptibility to infection, infection (ophthalmic), sterile abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy, arthropathy, aseptic necrosis of femoral head, aseptic necrosis of humoral head, bone fracture, Charcot-like arthropathy, lipotrophy, osteoporosis, rupture of tendon, steroid myopathy, vertebral compression fracture</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blindness, exophthalmoses, glaucoma, increased intraocular pressure, ophthalmic inflammation (ophthalmic), subcapsular posterior cataract, visual impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Anaphylactoid reaction, anaphylaxis, angioedema, hypersensitivity reactions, tissue sloughing (residue or slough at injection site), wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Venous thrombosis (Johannesdottir 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195365\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to methylprednisolone or any component of the formulation; systemic fungal infection (except intra-articular injection for localized joint conditions); intrathecal administration; live or attenuated virus vaccines (with immunosuppressive doses of corticosteroids); use in premature infants (formulations containing benzyl alcohol preservative only); immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) (IM administration only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindication: Methylprednisolone sodium succinate 40 mg vial only: Hypersensitivity to cow's milk or its components or other dairy products which may contain trace amounts of milk ingredients (known or suspected).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methylprednisolone tablets: Herpes simplex of the eye, vaccinia and varicella (except for short-term or emergency therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methylprednisolone acetate injection: Epidural or intravascular administration; intra-articular injections in unstable joints; herpes simplex of the eye, vaccinia and varicella (except for short-term or emergency therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methylprednisolone sodium succinate: Epidural administration; herpes simplex keratitis, vaccinia and varicella, arrested tuberculosis, acute psychoses, Cushing syndrome, peptic ulcer, markedly elevated serum creatinine (except for short-term or emergency therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195346\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermal changes: Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection. Avoid deltoid muscle injection; subcutaneous atrophy may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: High doses of methylprednisolone IV (usually doses of 1 g/day) may induce a toxic form of acute hepatitis (rare); serious hepatic injury may occur, resulting in acute liver failure and death. Time to onset can be several weeks or longer; resolution has been observed after discontinuation of therapy. Discontinue methylprednisolone if toxic hepatitis occurs. Avoid use of high doses in patients with a history of methylprednisone-induced toxic hepatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, cause activation of latent infections, mask acute infection (including fungal infections), prolong or exacerbate viral or parasitic infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to initiation of corticosteroids. Use with extreme caution in patients with <i>Strongyloides</i> infections; hyperinfection, dissemination and fatalities have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); discontinuation may result in clinical improvement (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression, or psychotic manifestations. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Septic arthritis: May occur as a complication to parenteral therapy; institute appropriate antimicrobial therapy as required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure (HF) and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute myocardial infarction (MI); corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma renal crisis incidence has been observed with corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Septic shock or sepsis syndrome: A study has failed to demonstrate efficacy in septic shock or sepsis syndrome treatment; use may increase mortality in some populations (eg, patients with elevated serum creatinine, patients who develop secondary infections after use).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Methylprednisolone <b>acetate</b> IM injection (multiple-dose vial) and the diluent for methylprednisolone <b>sodium succinate</b> injection may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017180\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2007). Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose dependent and produce a greater IOP in children &lt;6 years than older children treated with ophthalmic dexamethasone (Lam, 2005). Hypertrophic cardiomyopathy has been reported in premature neonates. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195422\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195351\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12601&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel.  Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of MethylPREDNISolone. Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of MethylPREDNISolone. Management: Consider methylprednisolone dose reduction in patients receiving strong CYP3A4 inhibitors and monitor for increased steroid related adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids (Systemic).  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel.  Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6472614\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses the placenta (Anderson 1981). Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (G&ouml;testam Skorpen 2016; Makol 2011; &Oslash;stensen 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For dermatologic disorders in pregnant women, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the lowest effective dose (Bae 2012; Leachman 2006).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased risk of perinatal mortality, preeclampsia, preterm birth, and low birth weight infants. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids should be used to control acute exacerbations or treat severe persistent asthma (ACOG 2008; GINA 2016; Namazy 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053998\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, serum glucose, potassium,  calcium, hemoglobin, occult blood loss, and clinical presence of adverse effects. Monitor intraocular pressure (if therapy &gt;6 weeks), weight, height, and linear growth of pediatric patients (with chronic use), assess HPA suppression </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195345\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">In a tissue-specific manner, corticosteroids regulate gene expression subsequent to binding specific intracellular receptors and translocation into the nucleus. Corticosteroids exert a wide array of physiologic effects including modulation of carbohydrate, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis. Moreover cardiovascular, immunologic, musculoskeletal, endocrine, and neurologic physiology are influenced by corticosteroids. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195364\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV (succinate): Within 1 hour; Intra-articular (IV acetate): 1 week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Intra-articular (IV acetate): 1 to 5 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 88% &plusmn; 23% (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV (succinate): 24 L &plusmn; 6 L (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to metabolites (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: IV: 1.9 &plusmn; 0.7 hours (age range: 12 to 20 years; Rouster-Stevens 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Oral: 2.5 &plusmn; 1.2 hours (Czock 2005); IV (succinate): 0.25 &plusmn; 0.1 hour (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 2.1 &plusmn; 0.7 hours (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV (succinate): 0.8 hours (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (1.3% [oral], 9.2% [IV succinate] as unchanged drug) (Czock 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054007\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of 1 g sodium succinate injection: 2.01 mEq; methylprednisolone sodium succinate 53 mg = methylprednisolone base 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195368\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (ReadySharp Methylprednisolone Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/mL (1): $349.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (MethylPREDNISolone Sodium Succ Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (1): $9.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (1): $36.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (SOLU-medrol Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $99.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $7.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (1): $11.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $27.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (1): $50.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (DEPO-Medrol Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $39.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (1 mL): $12.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/mL (1 mL): $22.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (MethylPREDNISolone Acetate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (1 mL): $10.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/mL (1 mL): $17.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (MethylPREDNISolone Acetate PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/mL (1 mL): $100.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Medrol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (21): $77.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (MethylPREDNISolone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (21): $30.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Medrol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $194.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $367.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (25): $128.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg (50): $398.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32 mg (25): $296.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MethylPREDNISolone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $142.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (25): $50.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg (50): $155.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32 mg (25): $115.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195370\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adrelan (PH);</li>\n      <li>Advantan (MX);</li>\n      <li>Adventan (ES);</li>\n      <li>Cipridanol (PY);</li>\n      <li>Cryosolona (MX);</li>\n      <li>Depo Medrol (AE, BH, JO, KW, LB, QA, SA);</li>\n      <li>Depo-Medrol (BB, CR, DO, EG, ET, GT, HN, IS, LU, LV, MX, NI, NO, PA, SI, SK, SV, UA, VN, ZW);</li>\n      <li>Depo-Medrone (IE, MT);</li>\n      <li>Epizolone-Depot (ET);</li>\n      <li>Flason (ID);</li>\n      <li>Flumethyl (ID);</li>\n      <li>Lexcomet (ID);</li>\n      <li>Lexxema (ES);</li>\n      <li>M-Nisol (LK);</li>\n      <li>M-Prednihexal (DE);</li>\n      <li>Madomed (TH);</li>\n      <li>Meapron (KR);</li>\n      <li>Medason (HK);</li>\n      <li>Medisolu (KR);</li>\n      <li>Medixon (ID, MY, PH);</li>\n      <li>Mednin (TW);</li>\n      <li>Medrate (DE);</li>\n      <li>Medrol (AE, BB, BE, BH, BM, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, GY, HN, HR, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KR, KW, LB, LT, LU, LV, LY, MT, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SI, SK, SR, SV, SY, TR, TT, VE, VN, YE, ZA);</li>\n      <li>Medrone (GB);</li>\n      <li>Melone 16 (TW);</li>\n      <li>Melsone (IN);</li>\n      <li>Menisone (TW);</li>\n      <li>Meprednisona All Pro (AR);</li>\n      <li>Mepresone (PH);</li>\n      <li>Mesolone (KR);</li>\n      <li>Metcor (ID);</li>\n      <li>Metcort (PH);</li>\n      <li>Methylon (KR);</li>\n      <li>Methylpred (AU);</li>\n      <li>Methylprednisolone David Bull (LU);</li>\n      <li>Methysol (KR);</li>\n      <li>Metrite (LK);</li>\n      <li>Metypred (UA);</li>\n      <li>Neo-Drol (LK);</li>\n      <li>Nisolon-M (KR);</li>\n      <li>Predlitem (MX);</li>\n      <li>Prednivex (LK, PH);</li>\n      <li>Prednol (TR);</li>\n      <li>Prednox (PH);</li>\n      <li>Prena (KR);</li>\n      <li>Pretilon (ID);</li>\n      <li>Prolon (ID);</li>\n      <li>Sanexon (ID, LK);</li>\n      <li>Sol-U-Pred (LK);</li>\n      <li>Sologen (KR);</li>\n      <li>Solomet (FI);</li>\n      <li>Solu Medrol (BF, BJ, CI, ET, GH, GM, GN, KE, LK, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Solu-Medon (VN);</li>\n      <li>Solu-Medrol (AE, AU, BB, BG, BH, CL, CN, CR, CY, DO, EG, GT, HK, HN, HR, IS, JO, JP, KW, LB, LT, LU, LV, MX, MY, NI, PA, PK, QA, RO, SA, SI, SK, SV, TH, TR, UY, VN);</li>\n      <li>Solu-Medrone (IE, MT);</li>\n      <li>Solu-Moderin (ES);</li>\n      <li>Solu-Pred (MY);</li>\n      <li>Somidex (TH);</li>\n      <li>Sonicor (ID);</li>\n      <li>Thimelon (ID);</li>\n      <li>Thylmedi (VN);</li>\n      <li>Tisolon-4 (ID);</li>\n      <li>Tropidrol (ID);</li>\n      <li>Urbason (AT, CZ, DE, ES, HR, NL);</li>\n      <li>Urbason Retard (BE, IT);</li>\n      <li>Yalone (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy. <i>Obstet Gynecol.</i> 2008;111(2 Pt 1):457-464.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adams A, MacDermott EJ, and Lehman TJ, &quot;Pharmacotherapy of Lupus Nephritis in Children: A Recommended Treatment Approach,&quot; <i>Drugs</i>, 2006, 66(9):1191-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/16827597/pubmed\" target=\"_blank\" id=\"16827597\">16827597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R. Sinus bradycardia after intravenous pulse methylprednisolone. <i>Pediatrics</i>. 2007;119(3):e778-782.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17308245 /pubmed\" target=\"_blank\" id=\"17308245 \">17308245 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GG, Rotchell Y, and Kaiser DG, &quot;Placental Transfer of Methylprednisolone Following Maternal Intravenous Administration,&quot; <i>Am J Obstet Gynecol</i>, 1981, 140(6):699-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/7020419/pubmed\" target=\"_blank\" id=\"7020419\">7020419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al, &quot;Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation,&quot; <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. <i>J Pediatr</i>. 1982;101(1):137-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/7045314 /pubmed\" target=\"_blank\" id=\"7045314 \">7045314 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carpenter PA and Macmillan ML, &quot;Management of Acute Graft-Versus-Host Disease in Children,&quot; <i>Pediatr Clin North Am</i>, 2010, 57(1):273-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20307721/pubmed\" target=\"_blank\" id=\"20307721\">20307721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC), &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&quot; <i>MMWR Recomm Rep</i>, 2009a, 58(RR-4):1-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19357635/pubmed\" target=\"_blank\" id=\"19357635\">19357635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Consortium for Spinal Cord Medicine, &quot;Early Acute Management in Adults With Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Professionals,&quot; <i>J Spinal Cord Med</i>, 2008, 31(4):403-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18959359/pubmed\" target=\"_blank\" id=\"18959359\">18959359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo; <i>N Engl J Med</i>, 2003, 348(8):727-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12594318/pubmed\" target=\"_blank\" id=\"12594318\">12594318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper SD, Felkins K, Baker TE, Hale TW. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. <i>J Hum Lact</i>. 2015;31(2):237-239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25691380/pubmed\" target=\"_blank\" id=\"25691380\">25691380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czock D, Keller F, Rasche FM, H&auml;ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15634032/pubmed\" target=\"_blank\" id=\"15634032\">15634032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depo-Medrol (methylprednisolone) [prescribing information]. New York, NY: Pfizer; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ditzian-Kadanoff R, Ellman MH. How safe is it? High dose intravenous methylprednisolone. <i>IMJ Ill Med J</i>. 1987;172(6):432-434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/2892818 /pubmed\" target=\"_blank\" id=\"2892818 \">2892818 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drake LA, Dinehart SM, Farmer ER, et al, &ldquo;Guidelines of Care for Dermatomyositis. American Academy of Dermatology,&rdquo; <i>J Am Acad Dermatol</i>, 1996, 34(5 Pt 1):824-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/8632081/pubmed\" target=\"_blank\" id=\"8632081\">8632081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ebato T, Ogata S, Ogihara Y, et al. The clinical utility and safety of a new strategy for the treatment of refractory Kawasaki Disease. <i>J Pediatr</i>. 2017;191:140-144.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29173297/pubmed\" target=\"_blank\" id=\"29173297\">29173297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garin EH, Sleasman JW, Richard GA, Iravani AA, Fennell RS. Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. <i>Eur J Pediatr</i>. 1986;145(5):380-383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3792382 /pubmed\" target=\"_blank\" id=\"3792382 \">3792382 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2016. http://ginasthma.org/wp-content/uploads/2016/04/wms-GINA-2016-main-report-final.pdf. Updated 2016. Accessed March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Updated January 2014. Accessed May 14, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&ouml;testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Ann Rheum Dis</i>. 2016;75(5):795-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26888948/pubmed\" target=\"_blank\" id=\"26888948\">26888948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. <i>J Pediatr</i>. 2013;163(2):521-526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23485027/pubmed\" target=\"_blank\" id=\"23485027\">23485027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. <i>Lancet</i>. 2012;379(9826):1613-1620.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22405251/pubmed\" target=\"_blank\" id=\"22405251\">22405251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam DS, Fan DS, Ng JS, et al, &quot;Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,&quot; <i>Clin Experiment Ophthalmol</i>, 2005, 33(3):252-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15932528/pubmed\" target=\"_blank\" id=\"15932528\">15932528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard MB, &quot;Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,&quot; <i>Pediatrics</i>, 2007, 119 Suppl 2:S166-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17332238/pubmed\" target=\"_blank\" id=\"17332238\">17332238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liebling MR, Leib E, McLaughlin K, et al. Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial. <i>Ann Intern Med</i>. 1981;94(1):21-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/7447218 /pubmed\" target=\"_blank\" id=\"7447218 \">7447218 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas KG, Howrie DL, Phebus CK. Cardiorespiratory decompensation following methylprednisolone administration. <i>Pediatr Hematol Oncol</i>. 1993;10(3):249-255.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/8217541 /pubmed\" target=\"_blank\" id=\"8217541 \">8217541 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, and Amin S, &quot;Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management,&quot; <i>Drugs</i>, 2011, 71(15):1973-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marks SD and Tullus K, &quot;Modern Therapeutic Strategies for Paediatric Systemic Lupus Erythematosus and Lupus Nephritis,&quot; <i>Acta Paediatr</i>, 2010, 99(7):967-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20222881/pubmed\" target=\"_blank\" id=\"20222881\">20222881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Methylprednisolone tablets [prescribing information]. Peapack, NJ: Greenstone LLC; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller JJ 3rd. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. <i>Pediatrics</i>. 1980;65(5):989-994.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/6966050 /pubmed\" target=\"_blank\" id=\"6966050 \">6966050 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. <i>Eur J Pediatr</i>. 2008;167(10):1119-1123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18175148/pubmed\" target=\"_blank\" id=\"18175148\">18175148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27012010/pubmed\" target=\"_blank\" id=\"27012010\">27012010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations For Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. <i>Pediatrics</i>. 2012;129(1):e17-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22144699/pubmed\" target=\"_blank\" id=\"22144699\">22144699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. <i>Eur J Pediatr</i>. 2009;168(2):181-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18446365/pubmed\" target=\"_blank\" id=\"18446365\">18446365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M and Forger F, &quot;Management of RA Medications in Pregnant Patients,&quot; <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ost L, Wettrell G, Bjorkhem I, et al, &quot;Prednisolone Excretion in Human Milk,&quot; <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3998938/pubmed\" target=\"_blank\" id=\"3998938\">3998938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ponticelli C, Glassock RJ, and Moroni G, &ldquo;Induction and Maintenance Therapy in Proliferative Lupus Nephritis,&rdquo; <i>J Nephrol</i>, 2010, 23(1):9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20091481/pubmed\" target=\"_blank\" id=\"20091481\">20091481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rohatagi S, Barth J, M&ouml;llmann H, et al, &quot;Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration,&quot; <i>J Clin Pharmacol</i>, 1997, 37(10):916-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9505983/pubmed\" target=\"_blank\" id=\"9505983\">9505983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rouster-Stevens KA, Gursahaney A, Ngai KL, et al, &quot;Pharmacokinetic Study of Oral Prednisolone Compared With Intravenous Methylprednisolone in Patients With Juvenile Dermatomyositis,&quot;<i> Arthritis Rheum</i>, 2008, 59(2):222-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18240180/pubmed\" target=\"_blank\" id=\"18240180\">18240180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solu-Medrol (methylprednisolone) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strijbos E, Coenradie S, Touw DJ, Aerden L. High-dose methylprednisolone for multiple sclerosis during lactation: concentrations in breast milk. <i>Mult Scler</i>. 2015;21(6):797-798.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25583837/pubmed\" target=\"_blank\" id=\"25583837\">25583837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12601 Version 220.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50579346\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F195382\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F195383\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053999\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053992\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195358\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F195342\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054003\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F195375\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054002\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195438\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195434\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195365\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195346\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017180\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F195422\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195351\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6472614\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053998\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F195345\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F195364\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1054007\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F195368\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F195370\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12601|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">Methylprednisolone: Drug information</a></li><li><a href=\"topic.htm?path=methylprednisolone-patient-drug-information\" class=\"drug drug_patient\">Methylprednisolone: Patient drug information</a></li></ul></div></div>","javascript":null}